Contrary to popular belief,
lung cancer does not always originate from smoking. There are a
wide array of causes that can lead to NSCLC. These
include, but are not limited to:
A modular immunotherapy using surface-engineered
bacterial membrane vesicles (BMVs). Derived from the
BCG-vaccine, PROMISE allows quick mobilization of immune
cells, targeting and destroying cancer cells using both the BMV’s natural
ability to stimulate the innate immune system and induce
trained immunity, as well as the addition of
cancer-specific antigens, stimulating the
adaptive immune system. This approach makes PROMISE a
powerful, targeted treatment for lung cancer with minimal side effects.
BMV ISOLATION
ANTIGEN FACTORY
1. First, we combine the bacteria with our custom made plasmid.
This allows the bacteria to create a modular handle on it's membrane.
2. Then, we isolate the bacterial membrane vesicles.
3. After isolation we combine the vesicles via the modular handle with the
disease-specific antigens.
This creates the fully functionalized vesicles.
This is the key component of our vaccine!
The Future
Due to PROMISE's modular design it can be adjusted and
tailored to the individual by using personal cancer epitopes, as well as
that it can be expanded to different cancer types or even other diseases!
Just swap out the antigen, and it alerts the immune
system for something completely different. This is how
versatile PROMISE is.
